Engineered Extracellular Vesicles Mediated CRISPR-induced Deficiency of IQGAP1/FOXM1 Reverses Sorafenib Resistance in HCC by Suppressing Cancer Stem Cells
Overview
Authors
Affiliations
Background: Sorafenib resistance poses therapeutic challenges in HCC treatment, in which cancer stem cells (CSCs) plays a crucial role. CRISPR/Cas9 can be utilized as a potential technique to overcome the drug resistance. However, a safe, efficient and target specific delivery of this platform remains challenging. Extracellular vesicles (EVs), the active components of cell to cell communication, hold promising benefits as delivery platform.
Results: Herein we report the normal epithelial cell -derived EVs engineered with HN3(HLC9-EVs) show competing tumor targeting ability. Anchoring HN3 to the membrane of the EVs through LAMP2, drastically increased the specific homing of HLC9-EVs to GPC3Huh-7 cancer cells rather than co-cultured GPC3LO2 cells. Combination therapy of HCC with sorafenib and HLC9-EVs containing sgIF to silence IQGAP1 (protein responsible for reactivation of Akt/PI3K signaling in sorafenib resistance) and FOXM1 (self-renewal transcription factor in CSCs attributed to sorafenib resistance), exhibited effective synergistic anti-cancer effect both in vitro and in vivo. Our results also showed that disruption of IQGAP1/FOXM1 resulted in the reduction of CD133 population that contribute to the stemness of liver cancer cells.
Conclusion: By reversing sorafenib resistance using combination therapeutic approach with engineered EVs encapsulated CRISPR/Cas9 and sorafenib, our study foreshadows a path for a better, accurate, reliable and successful anti-cancer therapy in the future.
Li Q, He G, Yu Y, Li X, Peng X, Yang L Stem Cell Res Ther. 2024; 15(1):449.
PMID: 39578849 PMC: 11583673. DOI: 10.1186/s13287-024-04061-z.
Promising nanotherapeutics of stem cell extracellular vesicles in liver regeneration.
Guo N, Wang Y, Wen Z, Fan X Regen Ther. 2024; 26:1037-1047.
PMID: 39569342 PMC: 11576938. DOI: 10.1016/j.reth.2024.09.016.
Yan Z, Huang L, Zhang X, Yu X, Huang R Sci Rep. 2024; 14(1):18444.
PMID: 39117725 PMC: 11310191. DOI: 10.1038/s41598-024-67437-4.
Yoon A, Lee S, Kim J, Park Y, Koo T, Yun C Mol Ther. 2024; 32(10):3618-3628.
PMID: 39066480 PMC: 11489544. DOI: 10.1016/j.ymthe.2024.07.017.
Li X, Zhang C, Yue W, Jiang Y Front Immunol. 2024; 15:1362120.
PMID: 38962016 PMC: 11219812. DOI: 10.3389/fimmu.2024.1362120.